Evidence map›Paper›PMID 35443746›Full record

ArticleCell death & disease2022

Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less.

Federico Lucantoni, Ana M Benedicto, Aleksandra Gruevska, Ángela B Moragrega, Isabel Fuster-Martínez, Juan V Esplugues, Ana Blas-García, Nadezda Apostolova

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Federico LucantoniDepartamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.ORCID 0000-0001-5173-7836
Ana M BenedictoDepartamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.
Aleksandra GruevskaDepartamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.ORCID 0000-0003-4411-829X
Ángela B MoragregaDepartamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.ORCID 0000-0003-1568-2342
Isabel Fuster-MartínezDepartamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.
Juan V EspluguesDepartamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.
Ana Blas-García *FISABIO-Hospital Universitario Dr. Peset, Valencia, Spain.ORCID 0000-0001-7870-1470
Nadezda Apostolova *Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain. nadezda.apostolova@uv.es.ORCID 0000-0002-4487-2471
Universitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the main extracellular matrix-producing cells, activated hepatic stellate cells (HSC) are fundamental mediators of liver fibrosis (LF), and understanding their activation/inactivation mechanisms is paramount to the search for novel therapeutics. The antiretroviral drug Rilpivirine (RPV) has demonstrated a hepatoprotective effect in several animal models of chronic liver injury that is related to its antifibrogenic and apoptotic action in HSC. In the present study, we evaluated whether autophagy is implicated in the hepatoprotective action of RPV, as autophagy plays an important role in HSC transdifferentiation. We employed two standard mouse models of chronic liver injury - fatty liver disease and carbon tetrachloride (CCl

Indexed as

Hepatic Stellate CellsRilpivirineAnimalsAutophagyDisease Models, AnimalLiver CirrhosisMiceTransforming Growth Factor betaRilpivirineTransforming Growth Factor beta

Identifiers

PMID35443746
PMCPMC9021290
OpenAlexW4224264383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.